Astria Therapeutics, Inc.
US ˙ NasdaqGM ˙ US04635X1028
BU SEMBOL ARTIK AKTİF DEĞİL

SecurityATXS / Astria Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership77,714 shares
Latest Disclosed Value $ 416,547
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series ownership in ATXS / Astria Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 77,714 shares of Astria Therapeutics, Inc. (US:ATXS) valued at $416,547 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 77,714 shares of Astria Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $977,642 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Astria Therapeutics EC US04635X1028 77,714 0 0.00 417 0.48 0.0094
2025-05-28 2025-03-31 NP Astria Therapeutics EC US04635X1028 77,714 0 0.00 415 -40.35 0.0100
2025-02-25 2024-12-31 NP Astria Therapeutics EC US04635X1028 77,714 -10,551 -11.95 695 -28.53 0.0152
2024-11-26 2024-09-30 NP Astria Therapeutics EC US04635X1028 88,265 -4,646 -5.00 972 14.91 0.0184
2024-08-26 2024-06-30 NP Astria Therapeutics EC US04635X1028 92,911 5,547 6.35 845 -31.24 0.0172
2024-05-28 2024-03-31 NP Astria Therapeutics EC US04635X1028 87,364 39,509 82.56 1,230 234.88 0.0257
2024-02-26 2023-12-31 NP Astria Therapeutics EC US04635X1028 47,855 4,983 11.62 368 15.05 0.0078
2023-11-28 2023-09-30 NP Astria Therapeutics EC US04635X1028 42,872 0 0.00 320 -10.64 0.0083
2023-08-25 2023-06-30 NP Astria Therapeutics EC US04635X1028 42,872 12,472 41.03 357 310.34 0.0085
2021-05-27 2021-03-31 NP Catabasis Pharmaceuticals EC US14875P2065 30,400 0 0.00 88 33.85 0.0020
2021-02-25 2020-12-31 NP Catabasis Pharmaceuticals EC US14875P2065 30,400 0 0.00 65 -65.43 0.0017
2020-11-25 2020-09-30 NP Catabasis Pharmaceuticals EC US14875P2065 30,400 0 0.00 188 -3.59 0.0060
2020-08-27 2020-06-30 NP Catabasis Pharmaceuticals EC US14875P2065 30,400 30,400 195 0.0064
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.